S
Sera Economics
← US Companies

GILEAD SCIENCES, INC.

GILD · Nasdaq · CIK 0000882095

SIC 2836

Biological Products, (No Diagnostic Substances)

Category

Chemicals

Entity

operating

Incorp.

DE

Fiscal Y/E

1231

Source: SEC EDGAR · All filings on SEC →

Investment Indicators

ROE

37.48%

ROA

14.42%

Current Ratio

1.55

Gross Margin

24.02%

Operating Margin

40.59%

Net Margin

34.47%

Book Value/Share

$18.29

Financial Statements

In USD millions (per-share figures shown directly) · Financials as of: 2026-02-24

Income Statement

FY20252024202320222021
Cost of Revenue6,2346,2516,4985,6576,601
Operating Income10,0221,6627,6057,3309,918
Net Income8,5104805,6654,5926,225
EPS (Basic)6.840.384.543.664.96
EPS (Diluted)6.780.384.503.644.93

Balance Sheet

FY20252024202320222021
Total Assets59,02358,99562,12563,17167,952
Current Assets18,34219,17316,08514,44314,772
Cash & Equivalents5,4125,338
Current Liabilities11,81312,00411,28011,23711,610
Long-term Debt24,93726,71024,98725,22926,695
Total Equity22,70319,33022,83321,24021,069

Cash Flow

FY20252024202320222021
Operating CF10,01910,8288,0069,07211,384
Investing CF-4,793-3,449-2,265-2,466-3,131
Financing CF-7,745-3,433-5,125-6,469-8,877
CapEx563523585728579
Dividends Paid4,0033,9183,8093,7093,605

📄 SEC Filings

Other filings (89)
FWP

FWP

FWP

2026-05-14

Open →

424B5

424B5

424B5

2026-05-14

Open →

S-8

S-8

FORM S-8

2026-05-07

Open →

4

Insider Transaction

FORM 4

2026-05-04

Open →

4

Insider Transaction

FORM 4

2026-05-04

Open →

4

Insider Transaction

FORM 4

2026-05-04

Open →

4

Insider Transaction

FORM 4

2026-05-04

Open →

4

Insider Transaction

FORM 4

2026-05-04

Open →

4

Insider Transaction

FORM 4

2026-05-04

Open →

4

Insider Transaction

FORM 4

2026-05-04

Open →

4

Insider Transaction

FORM 4

2026-05-04

Open →

SCHEDULE 13G

SCHEDULE 13G

xslSCHEDULE_13G_X02/primary_doc.xml

2026-04-29

Open →

4

Insider Transaction

FORM 4

2026-04-29

Open →

144

144

xsl144X01/primary_doc.xml

2026-04-28

Open →

SCHEDULE 13D/A

SCHEDULE 13D/A

xslSCHEDULE_13D_X02/primary_doc.xml

2026-04-28

Open →

SC TO-T/A

SC TO-T/A

SC TO-T/A

2026-04-28

Open →

SC TO-T/A

SC TO-T/A

SC TO-T/A

2026-04-17

Open →

4

Insider Transaction

FORM 4

2026-04-16

Open →

4

Insider Transaction

FORM 4

2026-04-16

Open →

144

144

xsl144X01/primary_doc.xml

2026-04-15

Open →

144

144

xsl144X01/primary_doc.xml

2026-04-15

Open →

SC TO-T/A

SC TO-T/A

SC TO-T/A

2026-04-01

Open →

4

Insider Transaction

FORM 4

2026-03-30

Open →

144

144

xsl144X01/primary_doc.xml

2026-03-27

Open →

SCHEDULE 13G/A

SCHEDULE 13G/A

xslSCHEDULE_13G_X02/primary_doc.xml

2026-03-26

Open →

ARS

ARS

ANNUAL REPORT TO SECURITY HOLDERS

2026-03-20

Open →

DEFA14A

DEFA14A

DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS

2026-03-20

Open →

4

Insider Transaction

FORM 4

2026-03-17

Open →

4

Insider Transaction

FORM 4

2026-03-17

Open →

144

144

xsl144X01/primary_doc.xml

2026-03-16

Open →

144

144

xsl144X01/primary_doc.xml

2026-03-16

Open →

4

Insider Transaction

FORM 4

2026-03-12

Open →

4

Insider Transaction

FORM 4

2026-03-12

Open →

4

Insider Transaction

FORM 4

2026-03-12

Open →

4

Insider Transaction

FORM 4

2026-03-12

Open →

4

Insider Transaction

FORM 4

2026-03-12

Open →

4

Insider Transaction

FORM 4

2026-03-12

Open →

SC TO-T

SC TO-T

SC TO-T

2026-03-06

Open →

4

Insider Transaction

FORM 4

2026-03-02

Open →

4

Insider Transaction

FORM 4

2026-03-02

Open →

4

Insider Transaction

FORM 4

2026-03-02

Open →

4

Insider Transaction

FORM 4

2026-03-02

Open →

4

Insider Transaction

FORM 4

2026-03-02

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-27

Open →

SC TO-C

SC TO-C

SC TO-C

2026-02-23

Open →

SCHEDULE 13D

SCHEDULE 13D

xslSCHEDULE_13D_X01/primary_doc.xml

2026-02-23

Open →

SC TO-C

SC TO-C

SC TO-C

2026-02-23

Open →

4

Insider Transaction

FORM 4

2026-02-18

Open →

4

Insider Transaction

FORM 4

2026-02-18

Open →

4

Insider Transaction

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

2026-02-17

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-17

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-17

Open →

3

3

FORM 3

2026-02-12

Open →

SCHEDULE 13G/A

SCHEDULE 13G/A

xslSCHEDULE_13G_X01/primary_doc.xml

2026-02-12

Open →

SCHEDULE 13G/A

SCHEDULE 13G/A

xslSCHEDULE_13G_X01/primary_doc.xml

2026-02-12

Open →

4

Insider Transaction

FORM 4

2026-02-06

Open →

4

Insider Transaction

FORM 4

2026-02-05

Open →

4

Insider Transaction

FORM 4

2026-02-05

Open →

4

Insider Transaction

FORM 4

2026-02-05

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-05

Open →

SCHEDULE 13G

SCHEDULE 13G

xslSCHEDULE_13G_X01/primary_doc.xml

2026-02-05

Open →

4

Insider Transaction

FORM 4

2026-01-29

Open →

144

144

xsl144X01/primary_doc.xml

2026-01-28

Open →

4

Insider Transaction

FORM 4

2026-01-26

Open →

144

144

xsl144X01/primary_doc.xml

2026-01-23

Open →

144

144

xsl144X01/primary_doc.xml

2026-01-22

Open →

4

Insider Transaction

FORM 4

2026-01-21

Open →

144

144

xsl144X01/primary_doc.xml

2026-01-20

Open →

4

Insider Transaction

FORM 4

2026-01-16

Open →

4

Insider Transaction

FORM 4

2026-01-16

Open →

144

144

xsl144X01/primary_doc.xml

2026-01-15

Open →

144

144

xsl144X01/primary_doc.xml

2026-01-15

Open →

4

Insider Transaction

FORM 4

2026-01-05

Open →

4

Insider Transaction

FORM 4

2025-12-30

Open →

144

144

xsl144X01/primary_doc.xml

2025-12-29

Open →

4

Insider Transaction

FORM 4

2025-12-16

Open →

4

Insider Transaction

FORM 4

2025-12-16

Open →

144

144

xsl144X01/primary_doc.xml

2025-12-15

Open →

144

144

xsl144X01/primary_doc.xml

2025-12-15

Open →

4

Insider Transaction

FORM 4

2025-12-11

Open →

4

Insider Transaction

FORM 4

2025-12-11

Open →

4

Insider Transaction

FORM 4

2025-12-11

Open →

4

Insider Transaction

FORM 4

2025-12-01

Open →

4

Insider Transaction

FORM 4

2025-12-01

Open →

4

Insider Transaction

FORM 4

2025-12-01

Open →

4

Insider Transaction

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

2025-12-01

Open →

144

144

xsl144X01/primary_doc.xml

2025-11-28

Open →

144

144

xsl144X01/primary_doc.xml

2025-11-28

Open →

144

144

xsl144X01/primary_doc.xml

2025-11-26

Open →

GILEAD SCIENCES, INC. (GILD) — Biological Products, (No Diagnostic Substances) | Sera Economics